SCHEMBL12150476

SCHEMBL12150476

C[C@H]1[C@@H](OC(=O)c2ccccc2)[C@H](n2cnc(C(N)=O)n2)O[C@@H]1CO

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ ADORA1 P30542 2/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ GLA P06280 1/20 0.54
▸ EIF4E P06730 1/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ TOP1 P11387 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ THPO P40225 1/20 0.54
▸ PMP22 Q01453 1/20 0.54
▸ PNP P00491 3/20 0.42
▸ LGALS9 O00182 2/20 0.41
▸ LGALS1 P09382 2/20 0.41
▸ LGALS3 P17931 2/20 0.41
▸ LGALS7; LGALS7B P47929 1/20 0.41
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ POLB P06746 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12150424 0.92 LMNA (0.47) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL6912924 0.91 LMNA (0.57) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL12151509 0.90 LMNA (0.45) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL12150445 0.89 LMNA (0.43) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL12746699 0.89 LMNA (0.44) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL12300734 0.86 LMNA (0.48) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL12150422 0.86 LMNA (0.41) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL12300346 0.85 LMNA (0.43) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL12300349 0.84 LMNA (0.47) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL6912376 0.84 LMNA (0.48) LMNASMN1; SMN2ADORA1ALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139604-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2015-09-22 — — US disclosed
US-20150025039-A1 ANTIVIRAL PHOSPHONATE ANALOGS GILEAD SCIENCES, INC. 2015-01-22 — — US disclosed
US-8871785-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2014-10-28 — — US disclosed
US-20110288053-A1 ANTIVIRAL PHOSPHONATE ANALOGS GILEAD SCIENCES, INC. (US) 2011-11-24 — — US disclosed
US-20110071101-A1 Nucleoside Phosphonate Analogs BOOJAMRA CONSTANTINE G 2011-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025039-A1 ANTIVIRAL PHOSPHONATE ANALOGS TYMP, ITPA, PNP LMNA 2918/4885SMN1; SMN2 2517/4885ADORA1 1306/4885
US-20110071101-A1 Nucleoside Phosphonate Analogs TYMP, PNP, NUDT1 LMNA 1265/4885SMN1; SMN2 1122/4885ADORA1 232/4885
US-20110288053-A1 ANTIVIRAL PHOSPHONATE ANALOGS TYMP, ITPA, PNP LMNA 2918/4885SMN1; SMN2 2517/4885ADORA1 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback